Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
about
Multiple roles for nicotine in Parkinson's diseaseActivin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's diseaseThe locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural studyThe role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned ratsStriatal glutamate release in L-DOPA-induced dyskinetic animalsRole for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian miceNicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationThe role of GRK6 in animal models of Parkinson's disease and L-DOPA treatmentCell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domainPharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingAnatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway.Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced DyskinesiaSpontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's diseaseDeletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's diseaseSide effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.Bursting activity of substantia nigra pars reticulata neurons in mouse parkinsonism in awake and anesthetized states.Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion.Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian ratDopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.Phase-amplitude coupling, an indication of bursting in parkinsonism, is masked by periodic pulses.The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratOptogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasM4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesiaα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's diseaseEffects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's diseaseTargeting nicotinic receptors for Parkinson's disease therapy.D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.
P2860
Q22252514-B503DFDD-A044-4E27-B0EF-03C56AF2199DQ27309140-147AD279-21D5-45F7-B296-DBE095AB0905Q28477041-D747571E-A5D3-4396-9090-78B10F9550FEQ28482094-140AF465-5269-425F-A509-3A54DCD5E79BQ28485942-6441D54F-9E83-4DE1-B338-6C9D33C0053AQ30450052-92BA6822-BD0E-481C-BA6F-3788F1F20D27Q30475334-5132A60D-D887-46DD-8C57-53D5E1A47222Q30506209-1D89378F-67DA-4351-8E88-6C47D44F4946Q30650489-ED938FF1-2643-414E-9704-4C6A612E86AAQ30653115-226282EC-547D-48AB-92AC-3EB82D216876Q33428476-ECD55A6B-EDDA-419E-B9E1-63839E63D85BQ33555895-6249D6C1-EC7E-469C-ADC3-3720E06E6D36Q33559375-47CF3CBD-36A0-4A2B-8983-0F3A58B91AFDQ34279877-AD6AD1D5-E4A0-4FAE-83DB-F9071693D3AFQ34309950-A453DFC8-E716-49B4-B7B1-923287A34A7AQ34419833-D3AE4827-EB95-4253-918E-6B59C109B844Q34795714-15E58A60-A764-46A4-A444-8FE9A8273376Q35003086-A9600FD9-75D3-49E5-BB24-9D4717BC5FF2Q35038040-F47EA9B0-CA42-4906-AA6A-04D6934462D8Q35097046-CC4EC7EB-72FF-4A71-BBAA-860299D3CA71Q35163198-99A9EB8B-E119-4D7B-8013-5620AF7D01DDQ35188119-22FD807E-5B82-46CB-AB3A-44022BD55788Q35264378-43C2BCBB-104E-4BA5-8F64-80FC5CC4DF31Q35492255-D1ECB6C3-B472-455F-99CC-42A99BC93F43Q35526434-8EA936B8-2415-488D-9821-42FAF9AB6527Q35534149-448BAF6E-7753-4E87-890C-7C21533A0478Q35815701-1EC7074E-8506-4DEE-87B0-52C144F0E42FQ35828317-AE717F7C-D25B-47A6-BB04-2D11E4BDCC5DQ36563189-1129526A-037C-4C8E-9DA6-99FDF37F6DE6Q36729888-DCF1622D-4634-48EC-AAF5-E2FA244BC7C3Q36852272-7BCF20A4-68D9-495C-8EB4-68CF1E50E465Q36880148-4374D7A5-EF95-48C1-AD86-39697DDB42C9Q36892615-0ED51F2D-6A4B-45B9-96FD-7FD9B5A788FFQ36936930-FD7D408B-97E6-4BDC-97C4-D9A5EF4268D1Q37132571-2B51094D-5D50-460C-8A00-1C11B61E15A2Q37270927-4337688A-50AA-4C77-AB4D-8C71699DC349Q37280179-649913DB-D9F5-43AD-9CB4-FD60E3363F3CQ37301208-33DB2F37-486F-4F94-92CF-B546787DC401Q37916643-3AF6399E-FEB3-4DCF-9C44-3DDEF7EC1753Q38699002-627D57A4-C0C9-48DE-A3A0-7E9B85EBA117
P2860
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@en
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@nl
type
label
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@en
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@nl
prefLabel
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@en
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@nl
P1476
Ratings of L-DOPA-induced dysk ...... on's disease in rats and mice.
@en
P2093
M Angela Cenci
Martin Lundblad
P304
P356
10.1002/0471142301.NS0925S41
P478
P577
2007-10-01T00:00:00Z